THERAPEUTIC AGENT FOR ENDERMOSIS IN ORAL CAVITY

PURPOSE:To obtain a therapeutic agent for endermosis in the oral cavity effective against stomatitis or mucitis which are one of side effects caused by chemotherapy and radiotherapy of cancer. CONSTITUTION:This therapeutic agent for endermosis in the oral cavity contains a basic fibrobroblast growth factor (bFGF) as an active ingredient. An extract separated from an organ such as a hypophysis, a brain, the retina, a corpus luteum, an adrenal, the kidney, the placenta, the prostata or the thymus, a substance produced by a gene engineering technique such as recombinant DNA technique, etc., and further their modified substances capable of acting as a fibroblast growth factor are included in the bFGF contained as an active ingredient of the therapeutic agent. A polypeptide, produced by a gene engineering technique described in WO87/1728 and having a sequence of 154 amino acids represented by the formula is cited as a preferred example. A solution, a parenteral injection, a spray, a gelling agent, a cream, an ointment, a buccal tablet, etc., are cited as the dosage form of the therapeutic agent. The local administration is preferred as the administration method.